GlassScriptPhysician profile
Jason S Breed
NPI 1821301011
$6,921.87
in general payments reported to CMS, 2019-2025
44 companies · $1,153 in 2025
The $1,153 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,500 · 2020: $159 · 2021: $61.82 · 2022: $1,339 · 2023: $1,465 · 2024: $1,245 · 2025: $1,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,862.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $984.07 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $919.92 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $706.06 | 2019-2025 | |
| Glaxosmithkline, LLC. | $608.48 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $517.32 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $479.35 | 2019-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $278.46 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $266.03 | 2019-2024 | Steglatro, Belsomra, Vaxneuvance |
| Amgen INC. | $227.41 | 2019-2024 | Otezla, Repatha, Evenity |
| Otsuka America Pharmaceutical, INC. | $174.29 | 2023-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Organon LLC | $165.71 | 2022-2024 | Nexplanon |
| Supernus Pharmaceuticals, INC. | $155.20 | 2019-2022 | Xyosted |
| Abbott Laboratories | $145.93 | 2019-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $138.58 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $116.66 | 2019-2025 | Spravato |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Breed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.